Precision BioSciences

6y

http://glassdoor.com/slink.htm?key=vMHJD

Precision BioSciences

6y

http://glassdoor.com/slink.htm?key=vMc3X

Precision BioSciences

6y

http://glassdoor.com/slink.htm?key=vMcOx

Precision BioSciences

6y

http://glassdoor.com/slink.htm?key=vMcOr

Precision BioSciences

6y

http://glassdoor.com/slink.htm?key=vM4iS

Precision BioSciences

6y

http://glassdoor.com/slink.htm?key=vMlSp

Precision BioSciences

7y

http://glassdoor.com/slink.htm?key=vMdZX

Precision BioSciences

7y

http://glassdoor.com/slink.htm?key=vMPu4

Precision BioSciences

7y

DURHAM, North Carolina, USA, November 27, 2018 – Precision BioSciences and Servier today announced that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for PBCAR0191, an allogeneic anti-CD19 CAR T therapy for B-cell acute lymphoblastic leukemia (B-ALL) and non-Hodgkin lymphoma (NHL). Upon trial initiation, PBCAR0191 will be Precision’s first clinical-stage product candidate. http://glassdoor.com/slink.htm?key=vMP4J